docetaxel,nivolumab,doxorubicin
sanofi,teva,aventis,bms,sopherion
['nivolumab', 'nivo', 'doxorubicin', 'docetaxel', 'gallant', '11518', 'sarcoma']
 #sarcoma poster discussion session at #asco2022 abs 11518 #gallant study on #gemcitabine w/ #doxorubicin, #nivolumab &amp; #docetaxel as 2nd/3rd-line therapy for advanced #sarcoma:
1 disease control rate 88.4%
2 med. pfs 4.6 mos &amp; os 6.2 mos
4 grd 3/4 trae reported #meded
Independent & international experts in #Sarcoma. #MedEd communicators, keeping you up to date with research & medical news in Sarcoma. Part of https://t.co/qM8Tca8PQX